Affymax Technologies, N.v.

Xenoport, Inc.

Medikine, Inc.

Glaxo Group Limited

Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Hoechst Marion Roussel

Affymax, Inc.

Glaxosmithkline LLC

Ronald W Barrett

William J Dower

Steven E Cwirla

Mark A Gallop

Michael C Needels

Peter J Schatz

Alice V Bakker

Christopher R Wagstrom

Christian M Gates

Stephen D Yanofsky

Kenneth C Cundy

Randall A Scheuerman

Nicholas C Wrighton

David J Duffin

Bruce P England

Christopher P Holmes

Qun Yin

Larry C Mattheakis

Christine L Martens

Palaniappan Balasubramanian

Surekha Podduturi

Sherril S Haselden

Min-Jia Chen

Derek Sloan

David N Baldwin

Jeff W Jacobs

Richard Wayne Hendren

Lubert Stryer

Michael C Pirrung

Steven A Sundberg

Fenmei Yao

Peter Virsik

Kerry J Koller

Randolph B DePrince

Jung K Lee

Thomas F Woiwode

Noa Zerangue

Haim Kedar

Jeffrey H Sugarman

Beatrice Ruhland

Alastair A Binnie

Beatrice Ruhland-Fritsch

Phillipe R Bovy

Ellen M Leahy

Richard S Pottorf

Tania Chernov-Rogan

Jay Edward Wrobel

Ariamala Gopalsamy

Daniel M Canafax

Sam Chan

Derek MacLean

Edith Lo Martin

Ann M Davis

Sherril S Johnson

Randoph B DePrince

Inkyung Park

Peter A Virsik

IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are disclosed. The IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are IL-7R agonists.

IL-7Rαγc ligand immunoglobulin fusion proteins

IL-7Rαγc binding compounds and pharmaceutical compositions comprising the IL-7Rαγc binding compounds are disclosed. IL-7Rαγc bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

IL-7R-α-γ binding compounds

IL-7R&#x3b1;&#x3b3;c binding compounds and pharmaceutical compositions comprising the IL-7R&#x3b1;&#x3b3;c binding compounds are disclosed. IL-7R&#x3b1;&#x3b3;c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

IL-7R&#x3b1;&#x3b3;c binding compounds

IL-2R&#x3b2;&#x3b3;c binding compounds, and pharmaceutical compositions comprising the IL-2R&#x3b2;&#x3b3;c binding compounds are disclosed. IL-2R&#x3b2;&#x3b3;c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.

IL-2R-&#x3b2;&#x3b3; binding compounds

Peptidyl IL-2R&#x3b1; ligands and compounds comprising the IL-2R&#x3b1; ligands are disclosed. The IL-2R&#x3b1; ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R&#x3b1; ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.

IL-2alpha receptor subunit binding compounds

IL-2R&#x3b2; ligands and IL-2R&#x3b3;c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R&#x3b2; ligands and/or the IL-2R&#x3b3;c ligands can be IL-2 receptor agonists.

IL-2Rgamma binding compounds

IL-2RBETA binding compounds

IL-7R&#x3b1; ligands and compounds comprising IL-7R&#x3b1; ligands are disclosed. The IL-7R&#x3b1; binding compounds include fusion proteins comprising the IL-7R&#x3b1; ligands and can act as IL-7R agonists.

IL-7R-&#x3b1; binding compounds

Dual receptor binding compounds comprising IL-2R&#x3b2;, IL-7R&#x3b1;, and R&#x3b3;c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Dual IL-2R and IL-7R binding compounds

IL-2RBeta binding compounds

IL-2R&#x3b2;  ligands and IL-2R&#x3b3;c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R&#x3b2;  ligands and/or the IL-2R&#x3b3;c ligands can be IL-2 receptor agonists.

IL-2R&#x3b3; binding compounds

A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.

Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use

Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a receptor

Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.

Treating or preventing restless legs syndrome using prodrugs of GABA analogs

Growing community of inventors

Saratoga, CA, United States of America

Ronald W Barrett